Cytokeratin AE1/AE3 immunolabeling in epithelioid hemangiosarcoma.
CD31
canine
cytokeratin AE1/AE3
epithelioid hemangiosarcoma
Journal
Veterinary pathology
ISSN: 1544-2217
Titre abrégé: Vet Pathol
Pays: United States
ID NLM: 0312020
Informations de publication
Date de publication:
20 Aug 2024
20 Aug 2024
Historique:
medline:
21
8
2024
pubmed:
21
8
2024
entrez:
21
8
2024
Statut:
aheadofprint
Résumé
Epithelioid hemangiosarcoma (EH), a rare histological variant of hemangiosarcoma, is reported in various animal species, including humans, dogs, cows, horses, and cats. Epithelioid hemangiosarcomas are composed of highly pleomorphic epithelioid cells arranged in cords, islands, nests, or solid cellular areas, similar to epithelial neoplasms. Moreover, in humans, approximately 50% of EHs have cytoplasmic immunolabeling for cytokeratin AE1/AE3 (CK AE1/AE3), making it challenging to distinguish them from carcinomas. This retrospective study assessed the CK AE1/AE3 immunolabeling in canine EH cases from 5 veterinary institutions. Immunohistochemistry for CD31 and CK AE1/AE3 was performed on 30 cases. CK AE1/AE3 immunolabeling was detected in 43% (13/30) of cases, with cytoplasmic labeling ranging from 5% to 100% of neoplastic cells. All tumors consistently had membranous immunolabeling for CD31. The CK AE1/AE3 immunolabeling pattern in canine EHs closely resembled those documented in humans, indicating a similar diagnostic challenge. Therefore, it is recommended to include a vascular immunohistochemistry marker, such as CD31, whenever EH is suspected, particularly in small incisional cutaneous and subcutaneous biopsies.
Identifiants
pubmed: 39165004
doi: 10.1177/03009858241273268
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3009858241273268Déclaration de conflit d'intérêts
Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: T.T.N.W. is employed by Antech Diagnostics and Mars Petcare Science & Diagnostics. The remaining authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.